Vasodilatory Drugs

  • Esen Özkaya
  • Kurtuluş Didem Yazganoğlu


Vasodilatory drugs include bosentan, diazoxide, epoprostenol, fenoldopam, hydralazine, minoxidil, nitrates such as isosorbide dinitrate, isosorbide mononitrate, nitroglycerin (glyceryl trinitrate), pentaerythritol tetranitrate, nitroprusside, nesiritide, nicorandil, and phosphodiesterase inhibitors such as cilostazol, amrinone, milrinone, enoximone, and sildenafil citrate. Sildenafil is mainly used for the treatment of erectile dysfunction.


Vasodilatory Hydralazine Minoxidil Nitrate Nitroglycerin patch Nicorandil Flushing Edema Hypertrichosis Lupus erythematosus Vasculitis Erythroderma Contact dermatitis Mucocutaneous ulcer 


  1. 1.
    Mansilla-Tinoco R, Harland SJ, Ryan PJ, Bernstein RM, Dollery CT, Hughes GR, et al. Hydralazine, antinuclear antibodies, and the lupus syndrome. Br Med J (Clin Res Ed). 1982;284:936–9.Google Scholar
  2. 2.
    Myers SA, Ahearn GS, Angelica Selim M, Tapson VF. Cutaneous findings in patients with pulmonary arterial hypertension receiving long-term epoprostenol therapy. J Am Acad Dermatol. 2004;51:98–102.PubMedCrossRefGoogle Scholar
  3. 3.
    Hsu HH, Chen JS, Chen RJ, Ko WJ, Kuo SW, Wu ET, et al. Long-term outcome and effects of oral bosentan therapy in Taiwanese patients with advanced idiopathic pulmonary arterial hypertension. Respir Med. 2007;101:1556–62.PubMedCrossRefGoogle Scholar
  4. 4.
    Wijitsettakul U, Pempongkosol S. The efficacy and safety of on-demand Elonza; a generic product of sildenafil in Thai men with erectile dysfunction. J Med Assoc Thai. 2013;96:683–8.PubMedGoogle Scholar
  5. 5.
    Litt JZ. Drug eruption reference manual. 19th ed. Boca Raton: CRC Press (Taylor and Francis Group); 2013.Google Scholar
  6. 6.
    Nawar T, Nolin L, Plante GE, Caron C, Montambault P. Long-term treatment of severe hypertension with minoxidil. Can Med Assoc J. 1977;117:1178–82.PubMedCentralPubMedGoogle Scholar
  7. 7.
    Salido R, Gómez-García FJ, Garnacho-Saucedo G, Galán-Gutiérrez M. Acquired generalized hypertrichosis due to diazoxide. Actas Dermosifiliogr. 2013;104:166–7.Google Scholar
  8. 8.
    Menter MA. Hypertrichosis lanuginosa and a lichenoid eruption due to diazoxide therapy. Proc R Soc Med. 1973;66:326–7.PubMedCentralPubMedGoogle Scholar
  9. 9.
    Koblenzer PJ, Baker L. Hypertrichosis lanuginosa associated with diazoxide therapy in prepubertal children: a clinicopathologic study. Ann N Y Acad Sci. 1968;150:373–82.PubMedCrossRefGoogle Scholar
  10. 10.
    Dawber RP, Rundegren J. Hypertrichosis in females applying minoxidil topical solution and in normal controls. J Eur Acad Dermatol Venereol. 2003;17:271–5.Google Scholar
  11. 11.
    Messenger AG, Rundegren J. Minoxidil: mechanisms of action on hair growth. Br J Dermatol. 2004;150:186–94.Google Scholar
  12. 12.
    Vedove CD, Del Giglio M, Schena D, Girolomoni G. Drug-induced lupus erythematosus. Arch Dermatol Res. 2009;301:99–105.PubMedCrossRefGoogle Scholar
  13. 13.
    Cameron HA, Ramsay LE. The lupus syndrome induced by hydralazine: a common complication with low dose treatment. Br Med J (Clin Res Ed). 1984;289:410–2.CrossRefGoogle Scholar
  14. 14.
    Bernstein RM, Egerton-Vernon J, Webster J. Hydralazine-induced cutaneous vasculitis. Br Med J. 1980;280:156–7.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Finlay AY, Statham B, Knight AG. Hydralazine-induced necrotising vasculitis. Br Med J (Clin Res Ed). 1981;282:1703–4.CrossRefGoogle Scholar
  16. 16.
    Cartee TV, Chen SC. Sweet syndrome associated with hydralazine-induced lupus erythematosus. Cutis. 2012;89:121–4.PubMedGoogle Scholar
  17. 17.
    Weiser GA, Forouhar FA, White WB. Hydralazine hoarseness. A new appearance of drug-induced systemic lupus erythematosus. Arch Intern Med. 1984;144:2271–2.PubMedCrossRefGoogle Scholar
  18. 18.
    Peterson LL. Hydralazine-induced systemic lupus erythematosus presenting as pyoderma gangrenosum-like ulcers. J Am Acad Dermatol. 1984;10:379–84.PubMedCrossRefGoogle Scholar
  19. 19.
    Neville E, Graham PY, Brewis RA. Orogenital ulcers, SLE and hydralazine. Postgrad Med J. 1981;57:378–9.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Hoffman B, Tunkel AR, Shuman M, Popkin M, Seth R. Minoxidil-induced systemic lupus erythematosus. Arch Intern Med. 1987;147:599–600.PubMedCrossRefGoogle Scholar
  21. 21.
    Yokogawa N, Vivino FB. Hydralazine-induced autoimmune disease: comparison to idiopathic lupus and ANCA-positive vasculitis. Mod Rheumatol. 2009;19:338–47.PubMedCrossRefGoogle Scholar
  22. 22.
    Pendergraft WF, Niles JL. Trojan horses: drug culprits associated with antineutrophil cytoplasmic autoantibody (ANCA) vasculitis. Curr Opin Rheumatol. 2014;26:42–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Gasser S, Kuhn M, Speich R. Severe necrotising leucocytoclastic vasculitis in a patient taking bosentan. BMJ. 2004;329:430.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Kounis NG, Zavras GM, Papadaki PJ, Soufras GD, Poulos EA, Goudevenos J, et al. Allergic reactions to local glyceryl trinitrate administration. Br J Clin Pract. 1996;50:437–9.Google Scholar
  25. 25.
    Aquilina S, Felice H, Boffa MJ. Allergic reactions to glyceryl trinitrate and isosorbide dinitrate demonstrating cross-sensitivity. Clin Exp Dermatol. 2002;27:700–2.PubMedCrossRefGoogle Scholar
  26. 26.
    Silvestre JF, Betlloch I, Guijarro J, Albares MP, Vergara G. Erythema-multiforme-like eruption on the application site of a nitroglycerin patch, followed by widespread erythema multiforme. Contact Dermatitis. 2001;45:299–300.PubMedCrossRefGoogle Scholar
  27. 27.
    Friedman ES, Friedman PM, Cohen DE, Washenik K. Allergic contact dermatitis to topical minoxidil solution: etiology and treatment. J Am Acad Dermatol. 2002;46:309–12.PubMedCrossRefGoogle Scholar
  28. 28.
    Rodríguez-Martín M, Sáez-Rodríguez M, Carnerero-Rodríguez A, Cabrera de Paz R, Sidro-Sarto M, Pérez-Robayna N, et al. Pustular allergic contact dermatitis from topical minoxidil 5%. J Eur Acad Dermatol Venereol. 2007;21:701–2.PubMedGoogle Scholar
  29. 29.
    Corazza M, Borghi A, Ricci M, Sarno O, Virgili A. Patch testing in allergic contact dermatitis from minoxidil. Dermatitis. 2010;21:217–8.PubMedGoogle Scholar
  30. 30.
    DiSantis DJ, Flanagan J. Minoxidil-induced Stevens-Johnson syndrome. Arch Intern Med. 1981;141:1515.Google Scholar
  31. 31.
    Ackerman BH, Townsend ME, Golden W, Bryan AB. Pruritic rash with actinic keratosis and impending exfoliation in a patient with hypertension managed with minoxidil. Drug Intell Clin Pharm. 1988;22:702–3.PubMedGoogle Scholar
  32. 32.
    Karaoui LR, Chahine-Chakhtoura C. Fatal toxic epidermal necrolysis associated with minoxidil. Pharmacotherapy. 2009;29:460–7.PubMedCrossRefGoogle Scholar
  33. 33.
    Al-Shouli S, Abouchala N, Bogusz MJ, Al Tufail M, Thestrup-Pedersen K. Toxic epidermal necrolysis associated with high intake of sildenafil and its response to infliximab. Acta Derm Venereol. 2005;85:534–5.PubMedGoogle Scholar
  34. 34.
    Ahearn GS, Selim MA, Tapson VF. Severe erythroderma as a complication of continuous epoprostenol therapy. Chest. 2002;122:378–80.PubMedCrossRefGoogle Scholar
  35. 35.
    Ryan FP. Erythroderma due to peritrate and glyceryl trinitrate. Br J Dermatol. 1972;87:498–500.PubMedCrossRefGoogle Scholar
  36. 36.
    Gallardo F, Gil A, Comín J, Molina L, Iglesias M, Pujol RM. Persistent painful indurated erythema secondary to bosentan. Acta Derm Venereol. 2006;86:186–7.PubMedGoogle Scholar
  37. 37.
    Nagai Y, Yamanaka M, Nishimura S, Nakano A, Hasegawa A, Ishikawa O. Drug eruption due to bosentan in a patient with systemic sclerosis. Mod Rheumatol. 2006;16:188–90.PubMedCrossRefGoogle Scholar
  38. 38.
    Smith VM, Lyon CC. Results of an electronic survey of British Association of Dermatologists members: nicorandil ulceration. Br J Dermatol. 2013;168:1136–7.PubMedCrossRefGoogle Scholar
  39. 39.
    Yap T, Philippou P, Perry M, Lam W, Corbishley C, Watkin N. Nicorandil-induced penile ulcerations: a case series. BJU Int. 2011;107:268–71.PubMedCrossRefGoogle Scholar
  40. 40.
    Claeys A, Weber-Muller F, Trechot P, Cuny JF, Georges MY, Barbaud A, Schmutz JL. Cutaneous, perivulvar and perianal ulcerations induced by nicorandil. Br J Dermatol. 2006;155:494–6.PubMedCrossRefGoogle Scholar
  41. 41.
    Ogden S, Mukasa Y, Lyon CC, Coulson IH. Nicorandil-induced peristomal ulcers: is nicorandil also associated with gastrointestinal fistula formation? Br J Dermatol. 2007;156:608–9.PubMedCrossRefGoogle Scholar
  42. 42.
    Yamamoto K, Matsusue Y, Horita S, Minamiguchi M, Komatsu Y, Kirita T. Nicorandil-induced oral ulceration: report of 3 cases and review of the Japanese literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011;112:754–9.PubMedCrossRefGoogle Scholar
  43. 43.
    Watson A, Al-Ozairi O, Fraser A, Loudon M, O’Kelly T. Nicorandil associated anal ulceration. Lancet. 2002;360:546–7.PubMedCrossRefGoogle Scholar
  44. 44.
    Trechot P, Barbaud A, Petitpain N, Claeys A, Schmutz JL. Nicorandil and ulcerations: a NAD/NADP and nicotinic acid-dependent side-effect? Br J Dermatol. 2008;158:1150–1.PubMedCrossRefGoogle Scholar
  45. 45.
    Trechot P, Jouzeau JY, Brouillard C, Scala-Bertola J, Petitpain N, Cuny JF, et al. Role of nicotinic acid and nicotinamide in nicorandil-induced ulcerations: from hypothesis to demonstration. Int Wound J. 2013. doi: 10.1111/iwj.12147.
  46. 46.
    Romano A, Giovannetti A, Caruso C, Rosato E, Pierdominici M, Salsano F. Delayed hypersensitivity to bosentan. Allergy. 2009;64:499–501.PubMedCrossRefGoogle Scholar
  47. 47.
    Allanore Y, Moachon L, Maury E, Isvy A, Kahan A. Bosentan-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. J Rheumatol. 2010;37:1077–8.PubMedCrossRefGoogle Scholar
  48. 48.
    Goldman BD. Lichenoid drug reaction due to sildenafil. Cutis. 2000;65:282–3.PubMedGoogle Scholar
  49. 49.
    Antiga E, Melani L, Cardinali C, Giomi B, Caproni M, Francalanci S, Fabbri P. A case of lichenoid drug eruption associated with sildenafil citratus. J Dermatol. 2005;32:972–5.PubMedCrossRefGoogle Scholar
  50. 50.
    Sehgal VN, Gangwani OP. Hydralazine-induced fixed drug eruption. Int J Dermatol. 1986;25:394.PubMedCrossRefGoogle Scholar
  51. 51.
    Ghosh SK, Bandyopadhyay D. Nonpigmenting mucosal fixed drug eruption due to sildenafil citrate. J Sex Med. 2009;6:3500–1.PubMedCrossRefGoogle Scholar
  52. 52.
    Wilsmhurst PT, Webb-Peploe MM. Side effects of amrinone therapy. Br Heart J. 1983;49:447–51.PubMedCentralPubMedCrossRefGoogle Scholar
  53. 53.
    Frishman WH, Brosnan BD, Grossman M, Dasgupta D, Sun DK. Adverse dermatologic effects of cardiovascular drug therapy: part III. Cardiol Rev. 2002;10:337–48.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2014

Authors and Affiliations

  • Esen Özkaya
    • 1
  • Kurtuluş Didem Yazganoğlu
    • 1
  1. 1.Department of Dermatology and VenereologyIstanbul University Istanbul Medical FacultyIstanbulTurkey

Personalised recommendations